Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
44
TXG Quote, Financials, Valuation and Earnings
Last price:
$16.74
Seasonality move
:
-12.36%
Day range:
$16.25 - $16.86
52-week range:
$6.78 - $20.34
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.21x
P/B ratio:
2.69x
Volume:
939.6K
Avg. volume:
2.5M
1-year change:
13.77%
Market cap:
$2.1B
Revenue:
$610.8M
EPS (TTM):
-$0.62
Analysts' Opinion
-
Consensus Rating10X Genomics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 4 Buy ratings, 12 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.36, 10X Genomics, Inc. has an estimated upside of 4% from its current price of $16.69.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 16.12% downside risk from its current price of $16.69.
Fair Value
-
According to the consensus of 16 analysts, 10X Genomics, Inc. has 4% upside to fair value with a price target of $17.36 per share.
TXG vs. S&P 500
-
Over the past 5 trading days, 10X Genomics, Inc. has overperformed the S&P 500 by 4.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
10X Genomics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
10X Genomics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter 10X Genomics, Inc. reported revenues of $149M.
Earnings Growth
-
10X Genomics, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter 10X Genomics, Inc. reported earnings per share of -$0.22.
Enterprise value:
1.7B
EV / Invested capital:
1.97x
Price / LTM sales:
3.21x
EV / EBIT:
--
EV / Revenue:
2.68x
PEG ratio (5yr expected):
-0.33x
EV / Free cash flow:
23.51x
Price / Operating cash flow:
28.23x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$457.7M
Return On Assets:
-8.01%
Net Income Margin (TTM):
-11.89%
Return On Equity:
-10.32%
Return On Invested Capital:
-9.26%
Operating Margin:
-21.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $591M | $629.7M | $641.8M | $151.7M | $149M | |
| Gross Profit | $380.6M | $413.9M | $457.7M | $105.4M | $100.9M | |
| Operating Income | -$191.8M | -$178.2M | -$140.8M | -$41.5M | -$32.2M | |
| EBITDA | -$151.5M | -$133.4M | -$98.5M | -$30.7M | -$20M | |
| Diluted EPS | -$1.91 | -$1.53 | -$0.62 | -$0.30 | -$0.22 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $744.1M | $629.4M | $562.3M | $593.9M | $659.8M | |
| Total Assets | $990.6M | $996.2M | $948.5M | $937.8M | $1B | |
| Current Liabilities | $100.4M | $126.9M | $104.7M | $121.2M | $147.3M | |
| Total Liabilities | $190.4M | $220.4M | $203.3M | $215M | $242.2M | |
| Total Equity | $800.2M | $775.8M | $745.2M | $722.8M | $785.1M | |
| Total Debt | $75.7M | $87.8M | $88.5M | $76.5M | $76.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$27.2M | $39.2M | $88.5M | $21.6M | $43.2M | |
| Cash From Investing | $87.2M | $32.1M | -$63.2M | -$3.6M | -$8.8M | |
| Cash From Financing | $13.1M | $12M | $9.1M | $156K | $617K | |
| Free Cash Flow | -$113M | $25M | $73M | $17.8M | $33.9M | |
TXG
Sector
Market Cap
$2.1B
$28M
Price % of 52-Week High
82.06%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-0.58%
-1.54%
1-Year Price Total Return
13.77%
-17.48%
Beta (5-Year)
2.148
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$16.18
200-day SMA
Buy
Level
$12.21
Bollinger Bands (100)
Buy
Level
12.13 - 16.39
Chaikin Money Flow
Sell
Level
-25.3K
20-day SMA
Sell
Level
$17.08
Relative Strength Index (RSI14)
Buy
Level
51.84
ADX Line
Buy
Level
30.33
Williams %R
Neutral
Level
-52.7815
50-day SMA
Buy
Level
$15.63
MACD (12, 26)
Buy
Level
4.34
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
7.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4019)
Buy
CA Score
(Annual)
Level (0.1107)
Buy
Beneish M-Score
(Annual)
Level (-3.6668)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (0.1818)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.
Stock Forecast FAQ
In the current month, TXG has received 4 Buy ratings 12 Hold ratings, and 0 Sell ratings. The TXG average analyst price target in the past 3 months is $17.36.
-
Where Will 10X Genomics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that 10X Genomics, Inc. share price will rise to $17.36 per share over the next 12 months.
-
What Do Analysts Say About 10X Genomics, Inc.?
Analysts are divided on their view about 10X Genomics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that 10X Genomics, Inc. is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is 10X Genomics, Inc.'s Price Target?
The price target for 10X Genomics, Inc. over the next 1-year time period is forecast to be $17.36 according to 16 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is TXG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for 10X Genomics, Inc. is a Hold. 12 of 16 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of TXG?
You can purchase shares of 10X Genomics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase 10X Genomics, Inc. shares.
-
What Is The 10X Genomics, Inc. Share Price Today?
10X Genomics, Inc. was last trading at $16.74 per share. This represents the most recent stock quote for 10X Genomics, Inc.. Yesterday, 10X Genomics, Inc. closed at $16.69 per share.
-
How To Buy 10X Genomics, Inc. Stock Online?
In order to purchase 10X Genomics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get TXG Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TXG
Sector
P/E ratio
--
23.89x
PEG ratio
-0.33x
-0.01x
P/B ratio
2.69x
1.82x
Price / LTM sales
3.21x
1.60x
Growth Metrics
TXG
Sector
Revenue growth
-1.75%
4.62%
Earnings growth
26.07%
10.88%
Revenue (5-year growth)
19.96%
6.5%
Earnings forecast
-$0.07
-$0.21
Profitability
TXG
Sector
Profitability FY 2024
$428.1M
$3.5M
Return on invested capital
-9.26%
-31.77%
Return on assets
-8.01%
-27.96%
Return on equity
-10.32%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
11
Estimated Next Earnings Date
Feb
5
Balance Sheet
TXG
Sector
Total cash
$482.1M
$26.3M
Short term investments
$49.3M
$25.7M
Total assets
$918.6M
$78M
Long term debt
$76.4M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
